Novartis AG (ADR)(NYSE:NVS) Has Strong Catalysts

Novartis has been an outperformer since the beginning of this year, gaining about 15% in value. Novartis AG (ADR) ( NYSE :NVS) Alcon division also posted a growth in the second quarter. Analysts believe that Entresto has a huge potential in Europe, where the heart disease market is rising and will reach a worth of over $16 billion in the next ten years.

The street is also expecting Cosentyx sales to grow in the latest part of 2017. Novartis is expected to get an approval from FDA for its blood cancer therapy treatment, CAR-T therapy, in October.

Over the current book year the total revenue will be 48,61 billion CHF (consensus estimates). This is slightly lower than 2016's revenue of 49,39 billion CHF.

Historical revenues and results Novartis plus estimates 2017

The analysts expect for 2017 a net profit of 10,99 billion CHF. The majority of the analysts expects for this year a profit per share of 4,75 CHF. So the price/earnings-ratio equals 17,35.

Huge dividend Novartis

Per share the analysts expect a dividend of 2,86 CHF per share. The dividend yield is then 3,47 percent. The average dividend yield of the pharmaceutical companies equals a limited 1,32 percent.

Most recent target prices around 89 CHF

The latest 3 recommendations for the pharmaceutical company were provided by Morgan Stanley , Jefferies & Co. and Deutsche Bank.

Novartis 's market capitalization is around 195,61 billion CHF.

At 17.31 the stock trades 0,42 percent higher at 82,4 CHF.

Historical stock prices Novartis

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.